---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-021414"
form_type: "8-K"
ticker: "LMAT"
cik: "0001158895"
company_name: "LEMAITRE VASCULAR INC"
filed_at: "2023-08-01T23:59:59+00:00"
generated_at: "2026-06-12T17:00:35.819046+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LeMaitre Q2 sales up 19% to $50.1M; EPS $0.36 (+127%); FY23 guidance raised; $0.14 dividend

## Summary
- Sales $50.1M, +19% (+16% organic) vs Q2 2022; operating income $9.5M (+63%).
- Net income $8.1M (+130%), diluted EPS $0.36 (+127%); adjusted EPS +25%.
- Gross margin 64.0% (down from 66.0%); EMEA +26%, APAC +21%, Americas +16%.
- FY23 guidance: sales $193M–$197.8M (+21%/+18% organic), EPS $1.23–$1.34 (ex-special $1.25–$1.35).
- Quarterly dividend $0.14/share, payable Aug 31, record Aug 17; $25M buyback authorized.

## SEC filing metadata
- accession: 0001437749-23-021414
- form_type: 8-K
- ticker: LMAT
- cik: 0001158895
- company_name: LEMAITRE VASCULAR INC
- filed_at: 2023-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1158895/000143774923021414/0001437749-23-021414-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1158895/000143774923021414/lmat20230801_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-021414
- JSON: https://secwatch.observer/filing/0001437749-23-021414.json
- Plain text: https://secwatch.observer/filing/0001437749-23-021414.txt

## Key facts
- Earnings Releases
  LEMAITRE VASCULAR INC reported the quarter ended June 30, 2023 results: revenue $50.1mm, net income $8.1mm, EPS $0.36. Guidance initiated.
  - Period: the quarter ended June 30, 2023
  - Revenue: $50.1mm
  - Net income: $8.1mm
  - EPS: $0.36
  - Guidance: initiated
  - Result: preliminary results
  source text: of vascular devices, implants and services, today reported Q2 2023 results, announced a $0.14/share quarterly dividend and provided guidance. Q2 2023 Financial Results ● Sales $50.1mm, +19% (+16% organic) vs. Q2 2022 ● Op. income $9.5mm, +63% (+8% adjusted) ● Op. margin 19% ● Net income $8.1mm, +130% (+27% adjusted) ● Earnings per diluted share $0.36, +127%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1158895/000143774923021414/0001437749-23-021414-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.